NA-921
Rett Syndrome and Fragile X
Phase 3Active
Key Facts
About Biomed
Biomed Industries is a late-stage private biotech with a broad and advanced pipeline targeting major neurodegenerative, metabolic, and cardiovascular diseases. Its core strategy is underpinned by a proprietary 'Unified Acceleration Platform,' a theoretical and AI-driven framework positing shared biological dysfunctions across these disease areas. The company has multiple Phase 2 and Phase 3 assets, most notably NA-931 for obesity and NA-831 for Alzheimer's, and one FDA-approved device, the MICROS Infusion System.
View full company profile